135 results about "Muscle damage" patented technology

The invention discloses a preparation method of sericin hydrogel, the method is as follows: first, weighting domestic silkworm fibroin deletion form mutation variety silkworm cocoon for LiBr or LiCl extraction and dialysis and purification to obtain a non-degradable sericin water solution with a mass percentage concentration of 0.1-4%; concentrating the sericin water solution to 1.5-10%, adding a cross-linking agent to the concentrated sericin water solution (wherein 2-500muL of the cross-linking agent is added into each L of the sericin water solution), fully mixing, and placing at 4-45 DEG C for 5 seconds to 36 hours to obtain the sericin hydrogel. The sericin hydrogel has biological activity and multiple functions, can be used as carrying growth factors, drugs and cell carriers treatment, and can be applied in repair of a variety of soft tissue injuries, including but not limited to skin damages, muscle damages, injuries of blood vessel, nerve injuries, myocardial damages, and the like, and treatment of diseases.

The present invention relates to compositions and methods use in pain reduction, including but not limited to, peripheral nerve blocks. In particular, the present invention relates to compositions and methods for the administration of perineural dexmedetomidine and ropivacaine in combination for increased antinociception in peripheral nerve blocks. In addition, this invention relates to any use of dexmedetomidine alone or in combination with other agents for the purpose of decreasing inflammation around peripheral nerves, thereby decreasing the potential for peripheral nerve injury. Further, the invention relates to the use of dexmedetomidine to reduce inflammation in the muscle to lessen or prevent muscle damage.

The present invention relates to a therapeutic substance and / or medicament and methods relating to the use of said substance and / or medicament for skeletal muscle regeneration using mesenchymal stem cells (MSCs) which can be applied directly or shortly after muscle damage or injury.

A performance enhancing sports drink is described. The drink, which is useful before, during, and after exercise, is specially developed to reduce lactate production, reduce perceived exhaustion, reduce muscle soreness (both actual muscle damage and perceived soreness), and reduce net fluid loss observed with exercise.

Dietary supplement compositions include an adaptogenic agent, an anti-inflammation agent, and an anti-oxidant. Methods for using dietary supplement compositions include (i) inhibiting, decreasing, and / or preventing delayed onset of muscle soreness (DOMS); (ii) inhibiting, decreasing, and / or preventing exercise-induced muscle damage; and / or (iii) modulating the expression of genes that are correlated with exercise-induced muscle damage.

A method of treating deep vein thrombosis in a limb of user includes applying a deep vein thrombosis treatment sleeve onto the limb of the user so that portions of the user's limb extend from opposite open ends of the deep vein thrombosis treatment sleeve; allowing the deep vein thrombosis treatment sleeve to conform to the limb and adhere to the limb over the area of the user's limb where the deep vein thrombosis resides through negligible compression suction adhesion; heating up the deep vein thrombosis treatment sleeve with a user's body heat so that the user barely notices the deep vein thrombosis treatment sleeve on the user's limb; and treating the deep vein thrombosis with the deep vein thrombosis treatment sleeve on the limb of the user over the area of the user's limb where the deep vein thrombosis resides. The treatment sleeve may also be used for treating a ligament or muscle injury in a joint of a user.

A sensory pelvic garment for pediatric patients with various pressure panels to assist with inhibition or facilitation for hypotonic or hypertonic muscle tone. The garment is used to treat pediatric patients with neurological muscular impairments by providing pressure to inhibit abnormal muscle tone and to facilitate postural awareness.

The invention provides methods for muscle repair or regeneration comprising administering therapeutically effective amounts of RAR agonists or stem cells that are pretreated with contact with a RAR agonist to a subject at a site of muscle damage. Additionally, the invention provides compositions comprising RAR agonist treated stem cells and methods of use of said cells for muscle repair or regeneration. In one embodiment, the stem cells are mesenchymal stem cells. In one embodiment, the RAR agonist is an RARγ agonist. In one embodiment, administration of the RAR agonist is begun during a period of increased endogenous retinoid signaling in the subject resulting from incurrence of the damaged muscle tissue.

The invention provides methods for muscle repair or regeneration comprising administering therapeutically effective amounts of RAR agonists or stem cells that are pretreated with contact with a RAR agonist to a subject at a site of muscle damage. Additionally, the invention provides compositions comprising RAR agonist treated stem cells and methods of use of said cells for muscle repair or regeneration. In one embodiment, the stem cells are mesenchymal stem cells. In one embodiment, the RAR agonist is an RARγ agonist. In one embodiment, administration of the RAR agonist is begun during a period of increased endogenous retinoid signaling in the subject resulting from incurrence of the damaged muscle tissue.

A pharmaceutical composition and method for regenerating cardiomyocytes in treating or repairing heart muscle damages or injuries caused by an ischemic disease. The pharmaceutical composition contains an active ingredient compound with a backbone structure of Formula (I). The active ingredient compound is capable of (a) increasing viability of myogenic precursor cells to enable said precursor cells to survive through an absolute ischemic period; (b) reconstituting a damaged blood supply network in said heart region where said injured muscle is located; and (c) enhancing cardiomyogenic differentiation efficiency of said precursor cells down cardiac linage, said steps being performed simultaneously or in any particular order.

The invention provides a dysphagia feedback therapy device and apparatus. The dysphagia feedback therapy device comprises a collecting and processing module, a correlating module, and a quantitative analysis module; the collecting and processing module is used for collecting continuous surface electromyogram signals generated by swallowing muscles in different swallow states in real time and processing the collected surface electromyogram signals to obtain a high-density dynamic potential pattern; the correlating module is used for correlating the position of the high-density dynamic potential pattern to the position of a swallowing muscle dissection mechanism to build a dynamic high-density physiological association diagram; the quantitative analysis module is used for analyzing the dynamic high-density physiological association diagram, collecting physiological parameters from the diagram and calculating swallowing muscle damage factors according to the physiological parameters. The apparatus comprises the dysphagia feedback therapy device. The dysphagia feedback therapy device and apparatus has the advantages that injured parts of swallowing muscles can be accurately located, injury degree of the swallowing muscles is obtained, and an appropriate therapeutic method can be selected according to the injured parts and the injury degree so as to perform feedback therapy.

Compositions and methods for treatment of individuals diagnosed with a dystrophin deficiency are disclosed. In particular, inhibitors of NFκB transactivation and / or inhibitors that suppress p65 expression are used to prevent and / or reverse muscle damage in animals or humans lacking dystrophin. Such compositions and methods are useful in the treatment of individuals with muscular dystrophy.

The invention discloses a method for preparing a tendon composite muscle decellularized material derived from natural tissue. The method comprises the following step: treating tendon composite muscletissue of any size with a PBS (Phosphate Buffer Solution) with a protease inhibitor, a PBS with KCl, a PBS with KI, a PBS with Triton X, a PBS with SDS (Sodium Dodecyl Sulfate) and a PBS with DNA (Deoxyribonucleic Acid) enzymes, thereby obtaining the tendon composite muscle decellularized material derived from natural tissue. By adopting the method, cells on tissue can be subjected to complete decellularization treatment which is gentle in condition, free of ECM (Extracellular Matrix) damage and rapid and stable. The obtained material not only is capable of simulating layered structures of natural tendon composite muscle to the maximum extent and relatively well retaining extracellular matrix components, but also has the advantages of very low immunogenicity, relatively good mechanical properties, and the like, can be applied to repairing clinical muscle damage and regression related diseases caused by various disease reasons.

The invention provides a system for measuring contractile torque of skeletal muscles, performing muscle training programs, and inducing contraction-induced injury. The system is versatile and precise to measure contractile torque, train muscles, and perform contraction-induced injury protocols on living rodents. The system also allows for repeated studies of the same animal over time, thus resembling longitudinal human studies, minimizing the effect of animal-to-animal variability, and reducing the total number of animals that need to be studied.

The invention relates to a functional beverage with ribose and L-carnitine and a preparation method of the functional beverage with ribose and L-carnitine, wherein the functional beverage comprises the following raw materials in parts by weight: 1-10 parts of the ribose, 0.5-5 parts of the L-carnitine, 1-60 parts of fructose, 0.1-10 parts of taurine, 0.0002-1.2 parts of vitamin mixtures, 0.2-2.3 parts of a preservative, 0.1-0.5 parts of an edible colorant, 0.6-1.2 parts of an edible essence and 850-1000 parts of purified water. The product provided by the invention has functions of resisting against fatigue, quickly supplementing physical energy, increasing explosive force of sport and quickly repairing muscle damage.

The invention provides cornus officinalis sieb health-care tea capable of lowering blood sugar. The health-care tea is composed of following raw materials in parts by weight: 10-50 parts of cornus officinalis sieb, 10-20 parts of fructus psoraleae, 10-20 parts of rhizoma polygonati, 10-20 parts of rehmannia glutinosa libosch, 10-20 parts of taxillus sutchuenensis, 10-20 parts of salvia miltiorrhiza, 10-20 parts of codonopsis pilosula, 10-20 parts of pyrrosia lingua, 10-20 parts of kadsura longepedunculata, 10-20 parts of fructus ligustri lucidi, 10-20 parts of artemisia apiacea, 10-20 parts of campsis grandiflora, 10-20 parts of poria cocos, 10-20 parts of prunella vulgaris, 10-20 parts of eupatorium fortunei, 10-20 parts of semen cassiae, 10-20 parts of gynostemma pentaphylla, 10-20 parts of radices trichosanthis and 10-20 parts of rhizoma atractylodis macrocephalae. Currently, the western medicine science has great achievement on researching and treating diabetes hyperlipemia; however, the problems in treating hepatic and renal function and digestive tract symptoms and muscle damages, caused by long-term medication, as well as the bounce effect after stopping the medicines still exist. In view of the syndrome differentiation and treatment features of the traditional Chinese medical science, traditional Chinese medicines have the advantage of small toxin side effect and the health-care treatment of the traditional Chinese medicines causes wide attention. The cornus officinalis sieb has the effects of lowering the blood pressure, the blood sugar, and the lipid, preventing the atherosclerosis, delaying aging, resisting bacteria and the like.

The invention relates to the field of muscle pathologies, more particularly to the field of diseases where skeletal muscle degeneration occurs. The invention describes transgenic mice that do not produce prolyl-hydroxylase-1, -2 or -3. It is revealed that the phenotype of the prolyl-hydroxylase 1 knock-out mouse is characterized by a protection of skeletal muscle atrophy due to a variety of muscle damages, especially ischemic insults. The invention thus relates to the use of molecules that can bind to prolyl-hydroxylase-1 for the prevention and / or treatment of skeletal muscle degeneration.

Compositions and methods for treatment of individuals diagnosed with a dystrophin deficiency are disclosed. In particular, inhibitors of NFκB activation, such as pyrrolidine dithiocarbamate (PDTC), have been shown to prevent and reverse muscle damage in animals lacking dystrophin. Such compositions and methods are useful in the treatment of individuals with muscular dystrophy.

A performance enhancing sports drink is described. The drink, which is useful before, during, and after exercise, is specially developed to reduce lactate production, reduce perceived exhaustion, reduce muscle soreness (both actual muscle damage and perceived soreness), and reduce net fluid loss observed with exercise.

In various embodiments, the present disclosure provides a method of treating a subject using laminin or a composition that includes laminin. In one embodiment, the method is used to enhance muscle regeneration, maintenance, or repair in a subject. In another embodiment, the method is used to promote wound healing. The method, in yet another embodiment, is used to prevent or reduce muscle damage or injury. In specific implementations of these methods, the laminin or composition that includes laminin is administered in a therapeutically effective amount. In some implementations, the laminin is a complete laminin protein. In other implementations, the laminin is a laminin fragment, a laminin derivative, or a laminin analogue.

Various pathophysiological states are determined by evaluating the rate of 17O-containing water production oxygen using proton MRI. The method can be used to identify viable but threatened myocardium, injured by viable muscle, penumbra tissue in a stroke patient, and the like.

The invention relates to a traditional Chinese medicine composition for dissolving blood stasis and dispelling cold and a preparation method and an application thereof; the traditional Chinese medicine composition is prepared by the following traditional Chinese medicines by weight: 8-15 parts of pseudo-ginseng, 6-12 parts of ligusticum wallichii, 5-10 parts of radix dipsaci, 3-8 parts of notopterygium roots, 3-8 parts of radix saposhnikoviae, 1-3 parts of asarum, 5-10 parts of cinnamon, 5-10 parts of kudzu roots, 1-5 parts of radix aconiti agrestis, and 5-10 parts of ginger. The traditional Chinese medicine composition for dissolving blood stasis and dispelling cold provided by the invention is developed according to traditional Chinese medicine theory and based on clinical experienced prescription; the traditional Chinese medicine composition of the invention has the main efficacy of activating blood and dissolving stasis, removing edema and relieving pain, dispelling wind and dispelling cold, freeing channels and activating collaterals, and has good edema removing and pain relieving effect on symptoms of bone fracture and muscle damage; the traditional Chinese medicine composition of the invention can promote the unlocking of channels and collaterals, eliminate symptoms such as menstrual blood obstruction, and has good recovery and healthcare effect on joint sting, ankylosis, and flexion-extension dysfunction.

The invention discloses an application of a hepatocyte growth factor gene in preparation of a medicament for preventing and / or treating pain. The paint caused by skin damages, the pain caused by muscle damages or neuropathic pain caused by nerve injuries can be significantly relieved by the application of the medicament. The application disclosed by the invention has an important application prospect and practical significance.

The present invention relates to a therapeutic substance and / or medicament and methods relating to the use of said substance and / or medicament for skeletal muscle regeneration using mesenchymal stem cells (MSCs) which can be applied directly or shortly after muscle damage or injury.

This invention describes novel methods of treating muscle damage, muscle wasting, muscle degeneration, muscle atrophy or reduced rates of muscle repair associated with various conditions such as muscular dystrophy, through the use of small-molecule PAI-1 inhibitors.

The invention discloses a sports beverage containing astaxanthin, taurine, nicotinamide mononucleotide and electrolyte and a preparation method. Every 250 mL of the sports beverage comprises 8-12 mg of the astaxanthin, 8-10 mg of the nicotinamide mononucleotide, 50-125 mg of the taurine, 25-75 mg of vitamin C, 0.1-0.3 mg of vitamin B6, 0.1-0.45 mg of vitamin B12, 5-10 g of glucose, a proper amountof essence, a proper amount of a suspending agent, 2.0 g of sodium chloride, 0.1 g of potassium chloride, 0.09 g of sodium bicarbonate, 0.02 g of monopotassium phosphate and 0.04 g of disodium hydrogen phosphate. The sports beverage containing the astaxanthin, the taurine, the nicotinamide mononucleotide and the electrolyte can remove free radicals generated by sports, relieve sports fatigue andmuscle aches, repair muscle injury, provide energy, supplement the electrolyte and enhance body endurance, and is a beverage capable of resisting oxidation and relieving physical fatigue.